We are live on ! Find out more
AVDL

Avadel Pharmaceuticals

Delisted

AVDL was delisted on the 11th of February, 2026.

84 hedge funds and large institutions have $282M invested in Avadel Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 24 increasing their positions, 21 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

92% more call options, than puts

Call options by funds: $7.02M | Put options by funds: $3.66M

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

14% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 21

4.9% more ownership

Funds ownership: 54.7% → 59.6% (+4.9%)

2% more funds holding

Funds holding: 82 → 84 (+2)

10% less capital invested

Capital invested by funds: $314M → $282M (-$31.9M)

Holders
84
Holders Change
+2
Holders Change %
+2.44%
% of All Funds
1.29%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
16
Increased
24
Reduced
21
Closed
13
Calls
$7.02M
Puts
$3.66M
Net Calls
+$3.36M
Net Calls Change
-$11.5M

AVDL Hedge Fund Activity: Q4 2021 in Review

84 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2021, worth a combined $282M — down 10% from $314M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new AVDL positions and 13 closed out — a net gain of 3 holders — while 24 added to existing stakes and 21 trimmed.

The largest buyer was Cowen and Company, adding an estimated $11M. The largest seller was Brandes Investment Partners, cutting an estimated $5.92M.

  • 84 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2021, up from 82 in Q3 2021.
  • Funds reported $282M of Avadel Pharmaceuticals stock for Q4 2021, down 10% quarter-over-quarter.
  • 16 funds opened new Avadel Pharmaceuticals positions in Q4 2021 and 13 closed out, a net change of +3 holders.
  • The largest Avadel Pharmaceuticals buyer in Q4 2021 was Cowen and Company, an estimated $11M added.
  • The largest Avadel Pharmaceuticals seller in Q4 2021 was Brandes Investment Partners, an estimated $5.92M sold.

Based on aggregated 13F filings for Q4 2021.